Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests safer surgery for miscarriage

NCT ID NCT06309927

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two surgical procedures for treating early pregnancy loss (miscarriage) up to 10 weeks: traditional suction curettage and a newer method using operative hysteroscopy. 100 women who choose surgery will be randomly assigned to one of the two methods. The goal is to see which approach leads to fewer complications, less scarring in the uterus, and better chances of future pregnancy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Early pregnancy loss (miscarriage) up to 10 gestational weeks 2. Able to give informed consent, and read/write in Hebrew Exclusion Criteria: 1. Incomplete abortion presenting as heavy vaginal bleeding and dilated cervix 2. Signs of infection and/or suspicion of septic abortion 3. Previous diagnosis of Mullerian anomalies - septate, bicornuate, unicornuate or didelphi uterus 4. Previous medical or surgical treatment in the current pregnancy 5. Previous diagnosis or past surgery for intrauterine adhesions 6. History of 2 or more prvious miscarriages 7. History of 2 or more cesarean sections 8. History of abdominal, vaginal or hysteroscopic myomectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early pregnancy loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Abortion, Spontaneous Asherman syndrome gynatresia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shamir Medical Center

    Be’er Ya‘aqov, 70200, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.